Hypogonadotropic secondary amenorrhea in diabetes: effects of central opiate blockade and improved metabolic control.
The effect of improving diabetic control on secondary hypogonadotropic amenorrhea was investigated in patients with insulin-dependent diabetes mellitus (IDDM). Second, the hypothesis that increased central (hypothalamic) opiate inhibition may have been responsible for the suppression of gonadotropin-releasing hormone (GnRH) was tested by observing the effect of a four-hour naloxone infusion (1.4 mg/hour) on serum gonadotropin levels. All known causes of secondary amenorrhea were excluded before patients were eligible for the study. The median duration of amenorrhea was six years, and median body weight was 101 percent of ideal. After six months of improved metabolic control (n = 5) using intensified conventional therapy or continuous subcutaneous insulin infusion, the level of glycosylated hemoglobin dropped from 11.8 +/- 0.9 percent to 8.5 +/- 0.5 percent (p less than 0.005), and body weight increased from 60.5 +/- 1.8 kg to 64.7 +/- 1.4 kg (p less than 0.02). Menses did not, however, return in any patient. There was no significant change in serum levels of estradiol, progesterone, dihydroxyepiandrosterone, testosterone, prolactin, basal or GnRH-stimulated luteinizing hormone, or follicle-stimulating hormone. There was no change in the levels of luteinizing hormone or follicle-stimulating hormone during the naloxone infusion either during poor metabolic control or after six months of improved metabolic control. In conclusion, a form of secondary hypogonadotropic amenorrhea was identified in patients with IDDM that did not remit with sustained improvements in metabolic control. It did not appear to be mediated through increased central opiate tone.
O'Hare
J A
JA
Joslin Diabetes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Eichold
B H
BH
Vignati
L
L
D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000209:etiology*; D001835:Body Weight; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications* / Q000628:therapy; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood / Q000172:deficiency*; D006801:Humans; D009270:Naloxone / Q000008:administration & dosage; D010906:Pituitary Hormone-Releasing Hormones / Q000008:administration & dosage
D006065:Gonadotropins, Pituitary; D010906:Pituitary Hormone-Releasing Hormones; D009270:Naloxone